Research News
Under the Microscope: OCRF’s 2015 Research Progress Report
(12/14/15) | In 2015, OCRF grantees made several significant advances in the fight against ovarian cancer, including: Pinpointing two genes that trigger ovarian cancer Identifying a new therapeutic strategy for clear cell ovarian cancer Discovering…
Our Response to the UKCTOCS ROCA & CA-125 Results
WASHINGTON — Today, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) of the University College London released the results of its study to determine if the risk of ovarian cancer algorithm (ROCA), when used yearly in conjunction…
Nintedanib Delays Progression of Advanced Ovarian Cancer
(December 4, 2015) According to the results of a phase III trial of over 1,000 women, women with advanced ovarian cancer gained significant delays in the progression of their disease when they were treated with the drug nintedanib plus…
OCRF Research Identifies Targetable Mutations in Low Grade Serous Ovarian Cancer
(December 2, 2015) Research funded in part by an OCRF grant to Rachel Grisham, MD has identified new, potentially targetable mutations in patients with low grade serous ovarian cancer. Dr…
OCRF Research Offers Insight on How Ovarian Cancer Grows
(December 1, 2015) Research funded in part by Ovarian Cancer Research Fund, and published in PNAS, offers new insights into how ovarian cancer grows—and the potential to stop it…
Better Outcomes for Ovarian Cancer Patients with History of Oral Contraceptive Use
(November 20, 2015) A study published in BMC Cancer demonstrates that ovarian cancer patients who had a history of oral contraceptive use had better outcomes than those who had not previously used them. Dr. Aminah Jatoi and co-author Dr…
Ten-year Survival Not Associated with BRCA Mutation Status
(Nov. 19, 2016) In research published this month in Gynecologic Oncology, a group of Canadian researchers have found that long-term survival is not associated with BRCA mutation status in ovarian cancer patients…
Meet OCRF’s 2016 Grantees
OCRF has awarded $5.2 million in new grants, bringing our total investment in ovarian cancer research to nearly $70 million…
OCRF Research Explains Limits of Cancer Immunotherapy Drugs
A new study of ovarian cancer cells from the University of Michigan Comprehensive Cancer Center, funded in part by an OCRF grant to Dr…
Research Round Up: AACR
Earlier this month, we attended the AACR conference Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, which highlighted many recent pre-clinical advancements in the treatment of ovarian cancer…
Precision Medicine Initiative
In January’s State of the Union Address, President Obama ushered in an exciting phase in new medical research by introducing the Precision Medicine Initiative (PMI)…
Precision Medicine Initiative
In January’s State of the Union Address, President Obama ushered in an exciting phase in new medical research by introducing the Precision Medicine Initiative (PMI)…